Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements

14 maj 2026 uppdaterad av: Thea Knowles, Michigan State University

Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements

The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.

Studieöversikt

Detaljerad beskrivning

Though intensive behavioral speech intervention is considered the "gold standard" for treating hypophonia in Parkinson's disease (PD), many individuals struggle to transfer or maintain these behavioral strategies into their daily communication. This is because PD, affecting over six million people worldwide, is a progressive, neurodegenerative disorder that also impairs cognition, sensorimotor integration, and fatigue. Speech amplification devices are a type of augmentative technology that have been shown to improve communication related outcomes in PD. Amplification devices increase the volume of a person's natural speech and can be used on their own or to augment behavioral speech outcomes. The specific acoustic mechanisms underlying these benefits are unknown, though previous evidence suggests that increased signal intensity alone is not responsible for improved auditory-perceptual outcomes. The overall goal of this proposal is to identify the relationship between acoustic and perceptual consequences of amplification devices with and without the use of behavioral speech strategies. Aim 1 of this proposal will quantify the acoustic and auditory-perceptual effects of speech amplification devices for talkers with PD. In addition to using an amplification device, participants will speak with both their habitual speech style and a hyperarticulated, clear speech style. Aim 2 will identify the contribution of resultant acoustic features as well as targeted acoustic enhancements that optimize intelligibility in amplified speech. Acoustic modifications that impact the relative contributions of low to high frequency spectral energy will be made to a subset of the speech recordings from Aim 1. These acoustic enhancements will serve to simulate potential technological improvements to amplification devices. Naïve listeners will hear the speech recordings made in Aims 1 and 2 and will provide measures of listener accuracy and effort. Improvements in speech intelligibility of amplified speech are hypothesized to be associated with acoustic measures that reflect relative greater high to low frequency components of the speech signal. The most positive change is hypothesized to occur when talkers combine behavioral speech strategies with amplification compared to behavioral changes or amplified speech alone. Furthermore, auditory-perceptual outcomes are hypothesized to improve following implementation signal enhancements that could be directly integrated into future amplification device development. Collectively, this study will identify ways to maximize speech treatment outcomes of speech amplification devices through behavioral changes made by the talker or acoustic enhancements to the device output itself. Results will guide behavioral treatment strategies and future device modifications that will improve the efficacy of speech amplifiers in this population. This work is innovative for establishing ways to leverage behavioral speech strategies with advances in augmentative technology for PD. It is theoretically significant for defining the role of spectral acoustics in auditory-perceptual outcomes in disordered speech. It is clinically significant for advancing patient-centered augmentative speech treatment technology for PD.

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Thea Knowles, PhD
  • Telefonnummer: 517-353-6401
  • E-post: thea@msu.edu

Studieorter

    • Michigan
      • East Lansing, Michigan, Förenta staterna, 48823
        • Rekrytering
        • Michigan State University
        • Kontakt:
          • Thea Knowles, PhD
          • Telefonnummer: 517-353-6401
          • E-post: thea@msu.edu
        • Huvudutredare:
          • Thea Knowles, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Dominant speakers of North American English
  • Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
  • Present with changes in their speech/voice

Exclusion Criteria:

  • History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
  • Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Speech Study
Single arm study: All speech conditions are administered.
Behavioral speech strategies + speech amplification

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Speech intensity
Tidsram: Day 1
Decibel sound pressure level (dB SPL) measured from speech audio recordings
Day 1
Voice quality
Tidsram: Day 1
Cepstral peak prominence smoothed (CPPS), measured in decibels (dB) from speech audio recordings
Day 1
Articulation
Tidsram: Day 1
Quadrilateral vowel articulation index, measured as a composite of first and second formants in Herz (Hz) across four vowels in speech audio recordings.
Day 1

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Speech intelligibility
Tidsram: From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
% words correctly understood by naive listeners (0% = no words correctly transcribed; 100% = all words correctly transcribed). Listener participants transcribe speech recorded by speaker participants.
From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
Perceived Listener Effort
Tidsram: From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.
% along a visual analogue scale (0 = "no effort required to understand the speech"; 100 = "maximal effort required to understand the speech"). Listener participants will rate speech recorded by speaker participants.
From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 mars 2024

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 maj 2028

Studieregistreringsdatum

Först inskickad

5 maj 2026

Först inskickad som uppfyllde QC-kriterierna

14 maj 2026

Första postat (Faktisk)

20 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera